EQRX EQRx, Inc.

EQRx Inc is a biotechnology company. Its pipeline programs include two pre-registrational oncology assets that have shown assuring Phase 3 data (aumolertinib and sugemalimab), and multiple other clinical-stage programs.

$4.61  +0.18 (4.06%)
As of 01/24/2022 15:59:54 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/15/2021
Outstanding shares:  487,632,615
Average volume:  811,800
Market cap:   $2,218,728,398
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -6.08
PS ratio:   0.00
Return on equity:   50.01%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy